FAM78B Inhibitors
FAM78B inhibitors encompass a variety of chemical compounds that decrease the functional activity of FAM78B through their actions on specific signaling pathways and cellular processes. Compounds such as LY 294002 and Wortmannin, both inhibitors of the PI3K pathway, can lead to a decrease in Akt signaling, and given that FAM78B is potentially linked to this pathway, such inhibition could result in diminished FAM78B activity. Staurosporine, with its broad-spectrum kinase inhibition, could also impact FAM78B if it is subject to regulation by kinases targeted by this compound. Similarly, the mTOR pathway, which can be inhibited by Rapamycin, may have a role in regulating FAM78B activity, and thus, inhibition of mTOR could lead to decreased FAM78B function. Src family kinases, which can be inhibited by PP 2, and tyrosine kinases inhibited by Dasatinib, might modulate FAM78B activity;therefore, these inhibitors could serve to indirectly diminish FAM78B's role in the cells. Additionally, MAPK signaling inhibitors, including U0126, SB 203580, and SP600125, target MEK1/2, p38 MAP kinase, and JNK respectively, and could reduce FAM78B activity if it is involved in these MAPK-regulated processes. Bortezomib's proteasome inhibition might also decrease FAM78B activity by affecting the turnover of regulatory proteins that modulate FAM78B.
The Akt signaling pathway, a common mediator of cellular survival and growth signals, can be targeted by Triciribine, which specifically inhibits Akt, potentially leading to reduced FAM78B activity if FAM78B is an Akt-dependent protein. PD 98059, another MAPK pathway inhibitor, specifically inhibits MEK, which would diminish ERK pathway signaling. If FAM78B acts downstream of the ERK pathway, inhibition by PD 98059 would result in decreased FAM78B activity. Collectively, these chemical inhibitors, by targeting various kinases and signaling pathways, can indirectly lead to the inhibition of FAM78B, providing a multi-faceted approach to diminishing its function in cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K). PI3K signaling is crucial for many cellular processes, including growth and survival. By inhibiting PI3K, LY 294002 can diminish the downstream Akt signaling, potentially leading to reduced activity of FAM78B if FAM78B is functionally linked to Akt signaling pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another strong inhibitor of PI3K. Wortmannin's inhibition of PI3K could lead to a decrease in Akt signaling, which may indirectly inhibit FAM78B activity if FAM78B operates downstream or in conjunction with Akt-dependent pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor known to target multiple kinases. If FAM78B's activity is regulated by specific kinases, Staurosporine could reduce its activity by inhibiting those kinases. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and thus can inhibit the mTOR signaling pathway. Since mTORC1 signaling influences various cellular processes, inhibition of this pathway by Rapamycin could diminish FAM78B activity if it is involved in mTORC1 mediated signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP 2 is a selective inhibitor of Src family tyrosine kinases. If FAM78B's functional activity is modulated by Src kinases, PP 2 could indirectly decrease FAM78B activity by inhibiting Src kinase signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream activators of ERK1/2 in the MAPK signaling pathway. If the MAPK pathway affects FAM78B activity, U0126 could reduce its activity by inhibiting this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. If FAM78B is involved in pathways regulated by p38 MAPK, inhibition of this kinase by SB 203580 could lead to a decrease in FAM78B function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), part of the MAPK family. If FAM78B operates within the JNK signaling pathway, inhibition of JNK by SP600125 could diminish FAM78B activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a potent inhibitor of several tyrosine kinases including Bcr-Abl and Src. By inhibiting these kinases, Dasatinib could indirectly inhibit FAM78B if its activity is regulated by tyrosine kinase signaling. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disrupt protein degradation pathways. If FAM78B activity requires proteasome-mediated degradation of regulatory proteins, Bortezomib could result in the inhibition of FAM78B activity. | ||||||